Patents Assigned to Qu Biologics Inc.
-
Patent number: 11819543Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.Type: GrantFiled: January 21, 2021Date of Patent: November 21, 2023Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
-
Patent number: 11226340Abstract: The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.Type: GrantFiled: April 26, 2017Date of Patent: January 18, 2022Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, David W. Mullins, Shirin Kalyan, Momir Bosiljcic, Monan Angela Zhang, Mark Bazett, Marcel Thalen, Dermot McGovern, Boyko Traychev Kabakchiev, Ho Pan Sham
-
Patent number: 10251946Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.Type: GrantFiled: May 1, 2015Date of Patent: April 9, 2019Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
-
Patent number: 10130692Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.Type: GrantFiled: January 26, 2012Date of Patent: November 20, 2018Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Patent number: 10086066Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.Type: GrantFiled: March 17, 2016Date of Patent: October 2, 2018Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 9775896Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.Type: GrantFiled: July 15, 2015Date of Patent: October 3, 2017Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 9320787Abstract: The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In selected embodiments, the invention provides methods for treating a cancer situated in the colon, using formulations of E. coli cells. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, inflammatory immune reaction at the site of administration.Type: GrantFiled: May 14, 2013Date of Patent: April 26, 2016Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 9320788Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora or exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.Type: GrantFiled: June 20, 2013Date of Patent: April 26, 2016Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 9107864Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.Type: GrantFiled: February 1, 2011Date of Patent: August 18, 2015Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Publication number: 20130337012Abstract: The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In selected embodiments, the invention provides methods for treating a cancer situated in the colon, using formulations of E. coli cells. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, inflammatory immune reaction at the site of administration.Type: ApplicationFiled: May 14, 2013Publication date: December 19, 2013Applicant: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 8501198Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.Type: GrantFiled: July 26, 2010Date of Patent: August 6, 2013Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 8034359Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.Type: GrantFiled: September 19, 2008Date of Patent: October 11, 2011Assignee: Qu Biologics Inc.Inventor: Harold David Gunn